{"title":"糖尿病中新型GLP-1模拟物:利昔那肽和阿比鲁肽","authors":"Jason Seewoodhary BSc, MRCP, John Davies MD, FRCP","doi":"10.1002/fps.79","DOIUrl":null,"url":null,"abstract":"<p><b>Lixisenatide and albiglutide are glucagon-like peptide-1 (GLP-1) agonists in clinical development that are similar to exenatide and liraglutide. This review critically considers the emerging evidence on the pharmacology, efficacy, safety and potential roles these two agents may have in clinical practice.</b></p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 2","pages":"20-22"},"PeriodicalIF":0.0000,"publicationDate":"2011-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.79","citationCount":"4","resultStr":"{\"title\":\"Novel GLP-1 mimetics in diabetes: lixisenatide and albiglutide\",\"authors\":\"Jason Seewoodhary BSc, MRCP, John Davies MD, FRCP\",\"doi\":\"10.1002/fps.79\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><b>Lixisenatide and albiglutide are glucagon-like peptide-1 (GLP-1) agonists in clinical development that are similar to exenatide and liraglutide. This review critically considers the emerging evidence on the pharmacology, efficacy, safety and potential roles these two agents may have in clinical practice.</b></p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"12 2\",\"pages\":\"20-22\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.79\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.79\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.79","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Novel GLP-1 mimetics in diabetes: lixisenatide and albiglutide
Lixisenatide and albiglutide are glucagon-like peptide-1 (GLP-1) agonists in clinical development that are similar to exenatide and liraglutide. This review critically considers the emerging evidence on the pharmacology, efficacy, safety and potential roles these two agents may have in clinical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
